Outlook: 1.The company has faced periodic production halts at its Reykjavik facility for modernization, resulting in net losses.2.Approvals from the FDA or European Medicines Agency (EMA) are highly unpredictable and critical for profitability.
AUC Score :
Short-term Tactic1 :
Dominant Strategy :
Time series to forecast n:
ML Model Testing : Modular Neural Network (Market News Sentiment Analysis)
Hypothesis Testing : Chi-Square
Surveillance : Major exchange and OTC
AUC Score :
Short-term Tactic1 :
Dominant Strategy :
Time series to forecast n:
ML Model Testing : Modular Neural Network (Market News Sentiment Analysis)
Hypothesis Testing : Chi-Square
Surveillance : Major exchange and OTC
1Short-term revised.
2Time series is updated based on short-term trends.